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Abstract 
 
ENDOCYTIC TRAFFICKING OF THE AMYLOID PRECURSOR PROTEIN IN 
RAT CORTICAL NEURONS 
  
Sahily Reyes-Esteves, B.S. 
 
Advisory Professor: Andrew J. Bean, Ph.D. 
 
Amyloid-beta (Aβ) aggregation and deposition into extracellular plaques is a hallmark 
of the most common forms of dementia, including Alzheimer’s disease. The Aβ-containing 
plaques result from pathogenic cleavage of amyloid precursor protein (APP) by secretases 
resulting in intracellular production of Aβ peptides that are secreted and accumulate 
extracellularly. Despite considerable progress towards understanding APP processing and 
Aβ aggregation, the mechanisms underlying endosomal production of Aβ peptides and their 
secretion remain unclear. Using endosomes isolated from cultured primary neurons, we 
determined that the trafficking of APP from the endosomal membrane into internal vesicles 
of late endosome/multivesicular bodies (MVB) is dependent on Endosomal Sorting 
Complexes Required for Transport (ESCRT) machinery. This implied that APP is 
ubiquitinated to allow ESCRT interactions. We then identified that the endosome-associated 
E3 ubiquitin ligase, UBE4B, is required for efficient endosomal APP trafficking. These 
results suggest that the efficiency of endosomal APP trafficking regulates Aβ generation. 
Decreasing Aβ levels in the brain may be a mechanism for disease modification in amyloid-
related dementia. These experiments elucidate cellular mechanisms that are amenable to 
regulation and could serve as potential therapeutic targets for amyloid pathologies.   
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Chapter 1. Introduction 
 
1.1 Alzheimer’s Disease  
Alzheimer’s disease (AD) is the most common human neurodegenerative disease 
(1–4). In the United States, close to 100,000 individuals die from AD every year (5) and 
those affected typically die within 10 years of diagnosis (6, 7). This disease manifests as 
progressive loss of cognitive ability and personality alterations, a process known as 
dementia. Despite decades of research, there is no disease-modifying therapy or diagnostic 
test for this insidious disease.  
AD was first described by Alois Alzheimer in publication from 1902 (8). The report 
described a 50-year-old female named Auguste Deter who experienced worsening paranoia 
and cognitive decline. Upon her death, an overall reduction in brain mass was noted, as was 
an accumulation of material inside and around the cells of her brain. During the 20th century, 
additional reports of patients experiencing similar symptoms led to the recognition that AD is 
the most common form of dementia.   
Like other neurodegenerative diseases, brains from AD patients are characterized by 
marked neuronal death resulting in loss of brain mass. Unlike other similar disorders, which 
tend to localize to specific brain regions, the loss of neurons in Alzheimer’s is robust and 
involves most of the cortex, as well as other key brain structures thought to be involved in 
memory formation such as the hippocampus (9–11). Histological examination of AD patient 
brains has revealed accumulation of protein aggregates inside and outside of cells, as 
illustrated on Figure 1A.  
The classical intracellular pathology observed in AD is called a neurofibrillary tangle 
(NFT), and is mostly composed of a hyperphosphorylated form of the Tau protein. Tau is a 
microtubule-associated protein that becomes abnormally phosphorylated in some 
pathological processes, like AD and other neurological disorders (12–16). 
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Hyperphosphorylated Tau results in neurotoxicity due to aggregation and inability to bind to 
cytoskeletal microtubules, which results in microtubule disassembly and cytoskeletal 
dysfunction (17–19). However, phosphorylated Tau is thought to be a secondary event in 
the development of AD for the following reasons. First, in animal models, anomalies in Tau 
or its phosphorylation lead to a phenotype with marked motor dysfunction (something 
absent in classical AD) that more closely resembles a different disease, frontotemporal 
dementia (FTD) (20–23). Second, Gotz et al. (24) observed that injection of a protein called 
amyloid beta (Aβ, whose role in AD will be discussed in detail later in this chapter) into the 
brains of a murine strain predisposed to the deposition of NFTs accelerated the formation of 
tangles. A study published simultaneously(25) showed that crossing a mouse predisposed 
to formation of Aβ with P301L mice led to accelerated formation of NFTs. Third, mice from a 
mutant strain predisposed to the formation of Aβ have memory impairments that are 
dependent on the expression of Tau, although these mouse models do not form NFTs. Tau-
mediated Aβ toxicity has also been observed in in vitro studies of neurons (26). Finally, 
phosphorylated Tau was observed to mediate Aβ toxicity in post-synaptic neurons by 
inducing excitotoxicity (which often leads to a seizure phenotype in AD animal models (27–
29).  While the controversy between these two potential etiologies for AD continues, the 
substantial evidence of a role for Aβ in human dementia merits its investigation.  
The extracellular pathology most commonly associated with AD is characterized by 
protein aggregates known as plaques (2–4, 18).  For reasons that are as yet unclear, 
amyloid plaques can be diffuse or dense (30), and they can form outside of neurons or 
inside blood vessel walls in the brain (31–34). This latter process is called cerebral amyloid 
angiopathy, and while it is a distinct diagnosis from AD, the two diseases can be co-morbid 
(34–36) and result in dementia. The protein aggregates that form plaques are composed 
primarily of Aβ (18, 37).  Aβ was first isolated and purified in 1984 (38, 39) and is a 4.2 kDa 
peptide most commonly found in extracellular aggregates in the brains of AD patients (3, 18, 
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37, 40). Aβ can exist in variants of 40-46 amino acids in length, with the 42-amino acid long 
variant, called Aβ42, being the form most prone to aggregation (41).  
The mechanism underlying the neuronal toxicity of Aβ in the central nervous system 
is still under investigation. In fact, some reports have linked Aβ to beneficial effects in the 
central nervous system, including enhanced neuron survival, synaptic modulation, and 
protection from oxidative stress (42–45). A prevailing hypothesis in the field is that the 
balance of Aβ production and clearance is disturbed in AD (41, 46). Excess Aβ production 
has been repeatedly shown to result in synaptic dysfunction, neuroinflammation, and 
oxidative stress, effects that are thought to ultimately produce neuronal death (41, 47–49). 
Although aggregation of Aβ is most commonly observed outside of neurons, several studies 
have reported that intraneuronal accumulation of Aβ is toxic to cells and antecedes the 
appearance of overt plaques in mouse models of AD (50–53). 
 
1.2 Amyloid Precursor Protein  
The amyloid precursor protein was identified in 1987 (4, 54) as the propeptide that 
led to Aβ formation. Since its discovery, APP has been strongly implicated in dementia (3, 4, 
18, 41, 55). Several lines of evidence support this idea. First, familial mutations (56–61) in 
this protein strongly correlate with the development of many forms of early-onset AD, and 
many of these mutations are shown to result in the formation of Aβ(62, 63). Second, the 
APP gene is located on chromosome 21, and patients with Down syndrome (who have a 
trisomy of this chromosome) have a high likelihood of developing early-onset AD (64–67). 
Finally, APP has been shown to be the only known protein that leads to formation of Aβ (68–
70).  
Amyloid precursor protein (APP) is a Type-I transmembrane protein that exists as 8 
isoforms (71–74) of 677-770 amino acids in length, of which the 695-amino acid variant is 
the most common in the human brain(75, 76). It is found in a variety of cell types (77–80), 
 4 
and several physiological roles in neurons have been investigated. In neurons, APP 
contributes to cell adhesion (81), neurite outgrowth (82–84), synaptogenesis (85), and 
neuronal migration (86). Mice lacking APP have mild deficits compared to these described 
functions (87, 88)suggesting that APP’s role in neuron physiology and normal function might 
be redundant with other related proteins, like the amyloid precursor-like proteins 1 and 2.  
Cleavage of amyloid precursor protein (APP) can be amyloidogenic (leading to the 
formation of Aβ) or non-amyloidogenic (3, 89–92)(Figure 2). APP cleavage by a member of 
the alpha-secretase family (predominantly ADAM10)(93, 94) can occur at the plasma 
membrane (PM). Alpha-secretase cleavage results in the APP soluble fragment APPsα and 
a membrane-bound C-terminal fragment (α-stub)(3, 89, 90). Cleavage of APP by an alpha-
secretase occurs in a portion of the Aβ sequence that renders the remaining peptides 
incapable of producing Aβ. The APPsα fragment mediates many of the described functions 
of full-length APP described above, such as neurite outgrowth and neuronal development 
(95–99). The C-terminal α-stub can be subsequently cleaved by the γ-secretase complex 
(composed of presenilin, nicastrin, APH-1, and PEN-2) to form the fragment P5. 
Interestingly, mutations in the presenilins are the most common form of inherited early-onset 
AD (100–102).   
If APP is cleaved by the β-secretase, Beta-site APP Cleavage Enzyme 1, (BACE-1), 
instead of an alpha-secretase, generation of the soluble APPsβ and a C-terminal fragment 
(β-stub, or C99) occur (103, 104). BACE-1 was first identified in 1999 by five independent 
groups (105–109). BACE-1 is a type-I transmembrane protein mostly expressed in the brain 
(3, 90, 103). BACE-1 enzyme activity has an optimal acidic pH such as is found in the Golgi 
and endosomes (90, 110–114). Increased expression of BACE-1 has been found in AD 
brains (115–117). Importantly, some familial AD-associated mutations in APP have 
increased susceptibility to cleavage by BACE-1(118) which then results in increased Aβ 
levels.  
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After BACE-1 cleavage, the β-stub can be further cleaved by the γ-secretase 
complex to yield the soluble Aβ species. The γ-secretase complex not only cleaves APP, but 
is essential for the cleavage of Notch, required for Notch signaling(119–121). Members of 
the γ-secretase complex have been localized to a variety of subcellular locations, although 
recent data suggests that the mature complex is mostly localized to the plasma membrane 
and the endosome/lysosome system(3, 122–125). For reasons that remain unclear, the γ-
secretase-mediated cleavage of APP can generate Aβ peptides of various lengths, 
accounting for the variety of Aβ species found in AD brains(3, 126–129).  
 
1.3 Endocytic trafficking of membrane proteins in mammalian cells  
APP is synthesized and trafficked through the secretory pathway en route to the 
plasma membrane. In the endoplasmic reticulum (ER) and Golgi apparatus, membrane 
proteins can be cleaved into mature variants, post-translationally modified, or removed for 
degradation (130–134). Many membrane proteins are inserted into the PM after trafficking 
through the ER/Golgi (133–137) and from there, various mechanisms (such as binding of 
ligands) can promote their internalization into the cell. In neurons, these events often occur 
as a result of synaptic activity. Once a membrane protein is internalized from the PM, it can 
travel in transport vesicles to endosomes. From endosomes, membrane proteins can either 
recycle to the PM, or can be degraded via fusion of the endosomes with the lysosome. 
Because the focus of this study is on the movement of APP through endosomes, the 
endocytic pathway will be discussed in further detail.  
The protein content of the plasma membrane is constantly renewed via insertion of 
proteins from the biosynthetic pathway and removal of other proteins via endocytosis. This 
dynamic state is a key regulatory mechanism that allows cells to adapt to their environment 
(138–140). This is especially important for neurons, where changes in surface protein 
expression (e.g. levels of glutamate receptors in the membrane are regulated by insertion 
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and endocytosis) can underlie functional alterations such as synaptic plasticity (141–145).  
The residence time of APP on the plasma membrane is approximately 10 minutes (83, 146–
149).  After internalization, vesicles containing membrane proteins (such as APP) can fuse 
with each other to form early endosomes, or fuse with existing early endosomes (150–152). 
Endosomes are organelles of approximately 500nm in diameter(153), that carry membrane 
proteins from the plasma membrane onto other cellular compartments for recycling or 
degradation(150–152). Endosomes mature from early into late endosomes by recruiting and 
discarding peripheral membrane proteins from the cytosol(154–159). Early endosomes are 
characterized by expression of markers such as EEA1, Rab5, Rab11, and transferrin (160–
163). From early endosomes, membrane proteins can bud in vesicles that can fuse with the 
PM or travel to secretory compartments (163, 164). Early endosomes are thought to mature 
into late endosomes, characterized by markers such as Lamp1, Tsg101, CD63, and Rab7 
(150, 154–159).  Late endosomes are formed when the limiting membrane invaginates and 
buds internally producing vesicles that accumulate in the endosomal lumen. The formation 
of these internal vesicles can occur as a result of the involvement of cytosolic proteins that 
bind the endosomal limiting membrane (a process that will be discussed in Section 1.5), 
although some studies have demonstrated that budding into the endosomal lumen can 
occur in the absence of such proteins, by inward budding of lipid-containing domains 
present on the endosomal limiting membrane (165–168). Regardless of the mechanism of 
internal vesicle formation, the development of late endosomes by these inward budding 
events also gives them their particular structure: a larger endosomal compartment 
containing smaller internal vesicles between 50-200nm in size (150, 152, 169–173). For this 
reason, the late endosome is also known as the multivesicular body (MVB) or the 
multivesicular endosome (MVE). MVBs can have different itineraries in cells: (a) they can be 
degraded upon fusion of the late endosome with the lysosome, or (b) fuse with the PM for 
release of its contents. If an MVB fuses with the PM, its internal vesicles are released as 
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exosomes into the extracellular space (174–179). Exosomes are nanovesicles of endosomal 
origin (178, 180–184) secreted by a wide variety of cells (178, 185–188), including neurons 
(189–192). After it transits to mature endosomes, APP can be degraded upon fusion of the 
MVB with the lysosome (68, 69, 193). However, multiple reports suggest that APP is present 
on exosomes (194–196) suggesting that APP may also be present on MVBs that fuse with 
the plasma membrane (69, 193, 196–199).  
 
1.4 Ubiquitination of membrane proteins for endocytic trafficking  
Many membrane proteins that move from early endosomes into late endosomes 
(particularly into the intraluminal vesicles within the late endosome) require ubiquitination to 
enable association with the sorting machinery at endosomes (200–204). Ubiquitin is a 76-
amino acid protein that can be conjugated to lysine residues of proteins as a post-
translational modification. It is highly conserved throughout eukaryotic organisms1, and the 
four genes (UBI1, UBI2, UBI3, and UBI4) that contain its code are present in both mammals 
and yeast. The presence of polyubiquitin chains on a protein often targets that protein for 
proteasomal degradation (204–208). The ubiquitination of a protein occurs in a series of 
steps mediated by the ubiquitin activating (E1), ubiquitin conjugating (E2), and ubiquitin 
ligase (E3) enzymes. There are two different E1 enzymes in mammalian cells, and these 
covalently bind and activate ubiquitin (207, 209, 210).  From there, ubiquitin is passed to the 
E2 enzyme, of which there are an estimated 40 different kinds (205–208, 211–213). E2 
enzymes will bind ubiquitin to the substrate, with the assistance of E3 ligases. The substrate 
specificity of ubiquitination is mediated by E3 ligases (214–217), of which the human 
genome is estimated to encode more than 600 unique proteins (214–216, 218). 
Ubiquitination is a reversible process and ubiquitin can be removed from proteins by the 
activity of deubiquitinating enzymes (219–223).  
 Proteins can be monoubiquitinated, multiubiquitinated (one ubiquitin is placed on 
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various lysine residues), or polyubiquitinated (various ubiquitin molecules form a chain 
anchored at one residue) (224–230). In polyubiquitination, two kinds of chains are 
commonly described: K48-linked chains and K63-linked chains. K48-linked chains are 
ubiquitin chains that bind to each other at lysine 48 of the ubiquitin sequence, forming 
branches that can be as long as 20 molecules. K63-linked chains occur after binding of 
additional ubiquitin molecules to lysine 63 of ubiquitin.  
The ubiquitination of a membrane protein can signal its degradation or can be a 
signal important for trafficking events. However, the correlation between the type of 
ubiquitination present on a target protein and the role of that ubiquitin for protein disposition 
has not been conclusively established (217, 231), although K48-linked chains have been 
suggested to constitute a specific signal for proteasomal degradation (202, 208, 232). Since 
the proteasome functions in the breaking down of cytosolic proteins, the observation that 
ubiquitination could occur on membrane proteins represented a challenge to the 
understanding of the field (206, 207, 233–236). Studies performed in the yeast 
Saccharomyces cerevisiae were the first to discover that ubiquitination of some membrane 
proteins was a signal for their further movement down endocytic compartments (237, 238). 
In mammalian systems, the first evidence of the role of ubiquitin in the trafficking of 
membrane proteins through the endocytic pathway came from the study of tyrosine kinase 
receptors, that were observed to become ubiquitinated after binding of their ligands (239–
242). For example, the epidermal growth factor receptor (EGFR) is monoubiquitinated prior 
to internalization from the PM (243, 244), although ubiqutination is not required for EGFR 
internalization (245–248). In these studies, cellular levels of EGFRs were unaffected by 
pharmacological proteasome inhibitors, suggesting their ubiquitination was not a signal for 
proteasomal degradation. Besides EGFR, a wide variety of membrane proteins can be 
ubiquitinated (249, 250). and both polyubiquitin and monoubiquitination can induce 
membrane protein internalization into endosomes (200, 251).  
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1.5 Recognition and trafficking of cargo by the ESCRT complexes:  
Once a membrane protein is ubiquitinated en route to or at endosomes, it can be 
recognized by a sorting machinery that assembles at the endosomal limiting membrane, 
known as the Endosomal Sorting Complexes Required for Transport (ESCRTs) (170, 172, 
248, 252–258). These proteins were discovered in a series of separate studies conducted 
between 1989 and 1992 by Rothman and Raymond (259–264). These investigations led to 
the discovery of a series of genes denominated the vacuolar protein sorting (Vps) genes. 
Some of the proteins encoded by these genes, denominated the ESCRT complexes, were 
discovered to be required for the degradation of many membrane proteins in the yeast 
vacuole (an organelle homologous to the mammalian endosome/lysosome) and 
subsequently, in mammalian endosomes (165, 203, 255, 256, 265–271).  
ESCRT complexes are well conserved across eukaryotes, likely because their role in 
protein homeostasis at endosomes is essential for normal cell function. This is highlighted 
by the fact that embryonic lethality is observed in mice that contain deletions or loss-of-
function mutations of various ESCRT components, such as hepatocyte growth factor-
regulated tyrosine kinase substrate (Hrs) and the tumor susceptibility gene 101 (Tsg101) 
(252, 262, 272–274). As would be expected, ESCRT deletion mutants often exhibit aberrant 
morphology such as enlargement and decreased internal vesicle formation (173, 256, 265, 
275). 
There are 4 ESCRT complexes: ESCRT-0, ESCRT-I, ESCRT-II, and ESCRT-III 
(summarized in Figure 3). ESCRT complexes assembly on the endosomal membrane by 
recruitment from the cytosol. First, a member of the ESCRT-0 family, Hrs, is recruited to 
endosomal membranes through its membrane-lipid targeting domain FYVE(272, 276, 277), 
although its P/Q domain has been observed to play a role in this process (278). At 
endosomes, Hrs first binds membranes through interaction with phosphatidylinositol 3-
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phosphate (PI3P) (256, 272, 276, 277). It can then bind to membrane proteins (often 
referred to as cargo) by recognizing ubiquitin with its ubiquitin-interacting motif (UIM)(251, 
265). After cargo recognition, Hrs recruits other ESCRT-0 components (which help cluster 
targeted cargo) as well as ESCRT-I components such as Tsg101. Tsg101 can also 
recognize ubiquitinated cargo (166, 255, 256, 279), and also aids in the recruitment of other 
ESCRT-I components. ESCRT-I formation leads to recruitment of the ESCRT-II complex 
components (165, 203, 268). The binding of these ESCRT complexes leads to invagination 
of the endosomal limiting membrane toward the endosomal lumen(280) in a process that is 
opposite to the invaginations observed from assembly of coat proteins (257, 281). ESCRT-II 
is thought to recruit ESCRT-III (165, 255, 256, 268), which is believed to aid the fission of 
invaginated endosomal membranes (255, 264, 268). Although there are several models 
about how this binding of ESCRT complexes leads to invagination of membranes (255, 
282), it is clear that ESCRT-0 proteins bind the ubiquitinated cargo and aid the assembly of 
the other ESCRT complexes. 
 
1.6 The ubiquitin factor E4B (UBE4B) in endocytic trafficking:   
 The E3 ligase, UBE4B, is a ubiquitinating enzyme first described as UFD2 in yeast 
(283). UBE4B is part of a family of E3 ligases known as ‘U-box’ ligases (284–287), because 
they possess a ‘U-box’ domain that confers their ubiquitinating capacity (287–291). The ‘U-
Box’ contains the binding site for the two E2 ligases known to bind UBE4B, UbcH5c and 
Ubc4 (287–292). UBE4B has at times been catalogued as a separate class of E3 ligase 
(also known as E4 enzymes) that, aside from aiding the ubiquitination of specific substrates 
as an E3 ligase, can also aid in the placement of additional ubiquitin molecules to specific 
substrates (289, 293).  
UBE4B has been implicated in yeast survival after cell stress (284). In the adult 
mouse, UBE4B is predominantly expressed in neurons (285). In the brain, it has been 
 11 
suggested to have a role in degeneration following axonal injury(294). UBE4B is involved in 
the ubiquitination and subsequent degradation of abnormal accumulations of ataxin-3, an 
aggregated protein that underlies spinocerebellar ataxia (292). UBE4B can also bind and 
decrease levels of p53, a known tumor suppressor (295). Homozygous UBE4B deficiency 
results in embryonic lethality in mice due to anomalies in cardiac development (289), and 
heterozygous UBE4B deficiency results in severe motor defects and Purkinje cell 
degeneration.  These data suggest that UBE4B is essential for normal development of the 
heart, as well as maintenance of neuronal integrity in the brain.  
  Previous work from the Bean laboratory(296) has shown UBE4B is an endosomally-
active E3 ligase. In that study, UBE4B was recruited to endosomes by binding to the early 
ESCRT, Hrs, that mediates its interaction with EGFR. This study also observed that UBE4B 
can ubiquitinate EGFR (296).  The UBE4B-mediated EGFR ubiquitination is an obligatory 
step in efficient movement of EGFR from the endosomal limiting membrane into internal 
vesicles within the mature endosome. These data highlight UBE4B as an E3 ligase with an 
active role at the endosome, and open the doors for the discovery of new substrates for 
UBE4B-mediated ubiquitination at this cellular site.   
 
1.7 APP movement and Aβ production through the endocytic pathway:   
While BACE-1 is expressed in many subcellular locations, only the secretory 
pathway and the endocytic pathway contain sufficient expression(105) and adequately low 
pH for optimal activity of APP by BACE-1 (103, 297). Moreover, BACE-1 and APP colocalize 
at both of these locations (298–306). For this reason, both of these sites have been the 
focus of a variety of studies seeking to identify the key location of APP cleavage into Aβ (3, 
299, 300, 305–311). Endosomes are of particular interest as a potential site of BACE-1 
mediated APP cleavage for several reasons. First, blockade of APP internalization by 
clathrin-mediated endocytosis from the PM (312)or by removal of the YENP endocytosis 
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signal (146, 313, 314) decreased Aβ levels in conditioned media in several studies, 
including studies performed in neurons (315, 316). Synaptic activity mediates APP 
internalization from the PM and results in increased Aβ secretion (315–318). Moreover, 
synaptic activity results in colocalization of BACE-1 and APP in endosomal compartments 
(299, 300). These data suggest that the endocytic itinerary of APP is a crucial location for 
amyloidogenic cleavage.   
There is conflicting evidence for a role of ESCRTs in the sorting of APP at 
endosomes and the secretion of Aβ. Depletion of early ESCRT components (Hrs and 
Tsg101) resulted in decreased Aβ secretion in some experimental models (305, 307), 
whereas others (306)have found that the same manipulation results in greater Aβ secretion. 
If APP trafficking is ESCRT dependent, then APP must be ubiquitinated to enable ESCRT 
interaction, suggesting that there may be a specific E3 enzyme that ubiquitinates APP. 
Interestingly, the E3 ligase FBL2 ubiquitinates APP resulting in proteosomal degradation 
(319), although the differences in ubiquitination requirements likely mean that a different E3 
enzyme is required for endosomal trafficking. In this regard, our preliminary data suggest a 
role for the endosome-associated E3 ubiquitin ligase, UBE4B, in the degradation of APP.   
 
1.8 Hypothesis statement:   
This study investigated my hypothesis (Figure 1D) that under non-pathogenic 
conditions, trafficking of full-length APP into the MVB is dependent on a specific E3 
ligase, UBE4B, and the ESCRT machinery. Disruptions in MVB trafficking that delay 
APP sorting may result in amyloidogenic processing of APP.  
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Figure 1A. Pathological findings in Alzheimer’s disease (AD). (A) Accumulation of 
intracellular neurofibrillary tangles and extracellular amyloid plaques leads to neuronal 
dysfunction and death in AD. (B) Current understanding of the diseases processes behind 
AD suggests that these toxic accumulations lead to neuronal degeneration and death, as 
shown by decreased mass in affected brains.   
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Figure 1B. Processing of the amyloid precursor protein (APP). Amyloid precursor 
protein can be cleaved in two main pathways. In the non-amyloidogenic cleavage, APP is 
cleaved into APPsα, secreted into the extracellular space, and the α-stub. This cleavage 
occurs through the Aβ sequence, precluding amyloid production after alpha-secretase 
cleavage. The stub is further cleaved by the gamma secretase complex into the amyloid 
precursor protein intracellular domain (AICD) and P3. In amyloidogenic cleavage, APP 
cleavage by a beta-secretase (BACE-1 in the brain), leading to generation of APPsβ 
(released into the cytosol) and the β-stub, C99 (which faces vesicular lumens). Further 
cleavage by the gamma secretase complex generates AICD and Aβ. The subcellular site 
where this occurs is a matter of controversy and is the subject of this dissertation.  
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Figure 1C. Summary of ESCRT proteins involved in the endocytic trafficking of 
mammalian membrane proteins. ESCRTs are classified as 4 complexes in both mammals 
and yeast, and their metazoan names are illustrated in this schematic. ESCRT complexes 
sequentially bind ubiquitinated membrane proteins at the endosomal limiting membrane. 
These interactions are thought to mediate the necessary changes in membrane curvature 
that allow budding of vesicles containing membrane proteins into the endosomal lumen. 
Adapted from (255). 
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Figure 1D. Illustration of endocytic APP trafficking in neurons.  (A) APP traffics through 
endosomes in neurons, and this is an important site of amyloidogenic cleavage (Das 2016, 
Morel 2013). (B) In physiological trafficking of APP through endosomes, the full-length 
protein is moved into internal vesicles of the maturing endosome through engagement of 
cytosolic proteins. When this trafficking is altered, APP can get cleaved by the secretases at 
the endosomal limiting membrane into Aβ, which will accumulate in the endosomal lumen.  
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Chapter 2. METHODS 
2.1 Materials— Antibodies were purchased from the following commercial sources: C-
terminal APP (Sigma, A8717; 5ug/mL for immunoblotting, IB; 50ug/mL for 
immunocytochemistry, ICC), N-terminal APP (Clone 22C11, Millipore; 10ug/mL for ICC), 
mouse and rabbit MAP2 (MAB3418 and AB5622, Millipore; 5ug/mL); Rab7 (D95F2  for ICC,  
for IB; Cell Signaling), EEA1 (2.5 ug/uL for ICC, 0.25ug/ml for IB; Thermo Fisher), BACE-1 
(1ug/mL; Cell Signaling), Flotillin (Abcam), Alix (0.29 ug/ml; Abcam), Actin (0.3 ug/ml; 
Millipore), UBE4B (0.3 ug/ml; Abcam), Ubiquitin (1 ug/ul; Enzo), Hrs (1 ug/ul; Axxora). 
Chemical reagents were purchased from various sources: GW4869 (Cayman Chemical), β-
Secretase Inhibitor IV – CAS 797035-11-1 (also known as C3; Millipore Sigma), and anti-
fade DAPI mounting media (Life Technologies).  
 
2.2 DNA/RNA Constructs—Short hairpin RNAs directed against UBE4B 
(CCGGTGGACCAACTGACGGATATTTCTCGAGAAATATCCGTCAGTTGGTCCATTTTTG; 
TRCN0000338294) and a scrambled shRNA 
(CCGGCAACAAGATGAAGAGCACCAACTCGAGTTGGTGCTCTTCATCTTGTTGTTT; 
SHC002) were purchased from Mission® shRNA (Sigma).  
 
2.3 Mammalian Cell Culture— TLA-HEK 293T cells (ATCC) were maintained at 37°C in 
5% CO2, with DMEM (Life Technologies) and10% FBS (Sigma), and passaged using 0.05 % 
trypsin/EDTA.  
 
2.4 Primary Neuron Culture—Primary cortical neurons were obtained from E17-18 rat 
embryos as described (321, 322). Briefly, cortical brain tissue was extracted from rat 
embryonic brains, dissected on ice, enzymatically dissociated, and seeded (8 million cells) 
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on 100 mm2 plates coated with 50ug/mL Poly-D-Lysine (Millipore).  Neurons were 
maintained with Neurobasal Media (Life Technologies), 2% B27 (Life Technologies), 1% 
Glutamax (Life Technologies), and 1% Penicillin-Streptomycin (Sigma) under 5% CO2 at 
37°C. Media was replenished every 4 days. Experiments were carried out using neurons 
that had been cultured for 5-7 days in vitro unless otherwise specified.   
 
2.5 Immunocytochemistry—Neurons (1x106) were plated on coverslips coated with Poly-
D-Lysine.  After 5 days in culture, neurons were fixed with 4% paraformaldehyde (15 min at 
room temperature) and treated with 100mM glycine in PBS (10 min). Fixed neurons were 
permeabilized with 0.1% Triton X-100 (10 min), and blocked with 10% normal goat serum in 
PBS (60 min). Fixed neurons were incubated with primary antibodies (overnight at 4°C), 
washed 3x with PBS, and incubated with secondary antibodies (60 min at room 
temperature). Slides were washed 3x with PBS and mounted using anti-fade DAPI mounting 
media (Life Technologies). Neurons were examined using a TCS SPE microscope-camera 
(Leica).  
 
2.6 Discontinuous sucrose gradient for endosome enrichment— Endosomally-enriched 
fractions were obtained from neuron lysates by fractionation using a discontinuous sucrose 
gradient, as described (323, 324). Briefly, after 5-7 days in vitro (DIV) neurons were washed 
with PBS, and gently scraped from the plate using a rubber cell scraper. Neurons were 
collected by centrifugation (1500 x g for 5 min) and resuspended in homogenization buffer 
(HB; 20 mM HEPES pH 7.4, 0.25 M sucrose, 2 mM EGTA, 2 mM EDTA, and 0.1 mM DTT) 
containing a protease inhibitor cocktail (112 μM leupeptin, 3 μM aproptinin, 112 μM PMSF, 
and 17 μM pepstatin). Neurons were lysed by passage through a 22-g needle 20 times, or 
until 80% of cells were lysed as demonstrated by assessing trypan blue exclusion. Post-
nuclear supernatant (PNS) was obtained by centrifugation of lysed cells (2000 x g for 10 
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min). The concentration of sucrose in PNS was adjusted to 40.6% and PNS (440 μL) was 
loaded at the bottom of a 2ml ultracentrifugation tube and overlaid with three layers of 
sucrose: 35% sucrose (660 μL), 25% sucrose (440 μ L), and 8% sucrose (500 μL). All 
sucrose-containing solutions also contained imidazole (3mM) and EDTA (1mM, pH 7.4). The 
gradient was centrifuged (150,000 x g for 60 min, model TLS55; Beckman Coulter). After 
centrifugation, 200uL fractions were collected from the top of the gradient (10 steps per 
gradient). Fractions were diluted using at least 1:1 in HB and membranes were pelleted by 
centrifugation (150,000xg for 30 min). A summary of the steps of this gradient, and a sample 
gradient after centrifugation is shown in Figure 2A. 
 
2.7 Cytosol preparation— Mammalian cytosol: Rat brain cytosol was produced as 
described (Sun, JCB 2003). For cytosol prepared from rat cortical neurons, neurons were 
scraped and centrifuged (2000 x g for 5 min at 4 °C). This neuron pellet was resuspended in 
homogenization buffer (HB; described above) with protease inhibitors (112 μM PMSF, 3 μM 
aprotinin, 112 μM leupeptin, 17 μM pepstatin), and sonicated 3 times (8 pulses of 1 second 
at output control 2; Branson Sonifier 250, VWR Scientific). The resulting lysate was 
centrifuged (2000 x g for 10 min at 4°C) and the supernatant was further centrifuged 
(100,000 x g for 60 min at 4°C). The supernatant was collected as cytosol and protein 
concentrations were calculated using a BCA assay (Pierce).  
Yeast cytosol: Saccharomyces cerevisiae deletion strains (Dharmacon) were plated 
on YPD plates (20 g/L bactopeptone, 10g/L yeast extract, 16 g/L agar, 2% dextrose) with 
G418 (500 μg/mL), and incubated overnight at 30°C. The parental strain was cultured 
without antibiotic. Colonies were inoculated in YPD media (5 mL) and incubated overnight 
on a shaker at 30°C. A secondary culture of YPD media (50 mL) was inoculated with the 
overnight culture and grown until OD600 reached 0.8-1.0. Cells were collected (3000 x g for 
10 min) and washed with ddH2O, followed by TP buffer (20 mM Tris, pH 7.9; 0.5 mM EDTA; 
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10% glycerol; 50 mM NaCl, 112 μM leupeptin, 3 μM aproptinin, 112 μM PMSF, and 17 μM 
pepstatin). The final pellet was resuspended in 100 μL of TP buffer.  Cells were lysed using 
glass beads.  Lysate was centrifuged (3000 x g for 10 min), and the supernatant was 
collected and further centrifuged (100,000 x g for 60 min) to collect cytosol. Protein 
concentrations were calculated using a BCA assay (Pierce). The supernatant was divided 
into 160 μg aliquots and stored at -80 °C.  
 
2.8 Immunoprecipitation and Immunodepletion— For co-immunoprecipitation 
experiments, neurons were collected using a rubber scraper, followed by centrifugation 
(1500 x g for 5 mins). Neurons were lysed using RIPA Buffer (10 mM Tris-Cl pH 8, 1 mM 
EDTA, 0.5 mM EGTA, 1% Triton X-1000, 0.1% sodium deoxycholate, 140 mM NaCl) 
containing protease inhibitors (60 min at 4°C with end-over-end rotation) followed by 
centrifugation (20,000 x g for 10min). For immunodepletion experiments, rat brain cytosol 
was isolated from lysate that was centrifuged (100,000xg for 60min). Cytosol was then 
incubated with 1 μg of antibody per 100μg of cytosol with the addition of a protease inhibitor 
cocktail (overnight with end-over-end rotation). Samples were subsequently incubated with 
washed protein A agarose beads (15 μL) for 4h at 4°C. Following brief centrifugation (1000 x 
g for 3 seconds) to separate beads from supernatant, immunodepleted supernatant was 
collected for use in cell-free endosomal reconstitution assays (described below). For 
immunoprecipitation, beads were washed (3x with 1X PBS) prior to resuspension in sample 
buffer and immunoblotting.  
 
2.9 Cell-free endosomal reconstitution assay—A summary of this assay is presented in 
Figure 2B. Reconstitution of endosomal maturation (and formation of inwardly-budded 
vesicles) was performed as previously described (173, 296, 325), with some modifications. 
Briefly, early endosomes from primary neurons were obtained from a discontinuous sucrose 
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gradient (described above), and resuspended in HB. Each reaction (50 μL) contained 
endosomal membranes, mammalian cytosol (75μg) or yeast cytosol (160μg), and an ATP 
regeneration system (2 mM MgATP, 50 μg/mL creatine kinase, 8 mM phosphocreatine and 
1mM). Reactions were incubated (3 hours at 37°C) prior to analysis (as below).  
For experiments examining the movement of full-length APP into the endosomal 
lumen, reactions (as above) were followed by trypsin-treatment (10 μl of 0.25 μg/μL trypsin; 
30 min at 4°C) and centrifugation (20,000 x g; 30 min at 4°C). Supernatant was aspirated 
and pellet was resuspended in sample buffer for immunoblotting. Resultant blots were 
probed with an antibody that recognizes the C-terminal epitope APP (Sigma).  For 
experiments examining the generation of Aβ42, reactions were centrifuged (20,000xg for 30 
min at 4°C) and pellets were resuspended in HB for analysis by ELISA.   
Western blot densitometry was quantitated using Image J (NIH). For analysis of 
experiments using yeast cytosol, quantitation of immunoblot bands from deletion strains 
were normalized to bands obtained in reactions containing parental control. For analysis of 
experiments using mammalian cytosol, quantitation of immunoblot bands from reactions 
using depleted or transfected cytosol were normalized to immunoblot bands obtained in 
reactions containing IgG-treated cytosol.  
In experiments involving C3 (also known as β-Secretase Inhibitor IV – CAS 797035-
11-1), endosomal membranes were treated with drug (20uM) or vehicle for 15 minutes at 
37°C, prior to use in reactions containing cytosol and ATP regeneration system.  
 
2.10 Cell transfection and lentivirus production—TLA-HEK 293T cells were transfected 
with third-generation lentiviral packaging plasmids (pMLg/pRRE, pRSV-Rev, pMD2.g; 
Addgene) and target DNA using Lipofectamine 3000 (Life Technologies), according to 
manufacturer’s instructions. After 48 hours, media containing virus was passed through a 
0.22um PVDF filter (VWR) and applied to neurons. After 24 hours, virus was removed and 
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conditioned media (media that has been previously exposed to neurons, and as such, 
contains secreted factors that might aid neuronal survival in culture) added to neurons. For 
experiments in which exosome production was measured after lentiviral transduction, 
conditioned media was centrifuged (150,000 x g for 2 hours), passed through a 0.22um 
filter, and warmed to 37°C prior to addition to neuronal cultures. 
 
2.11 Immunoblotting— Samples were separated using SDS-PAGE and transferred onto 
nitrocellulose membranes (Genesee). All primary antibodies were incubated overnight at 
4°C, and all secondary antibodies were incubated for 60 min at room temperature. 
Membranes were incubated with ECL 2 (Pierce) and developed using a Typhoon FLA 7000 
(GE).  
 
2.12 ELISA— The murine Aβ42 enzyme-linked immunosorbent assay (ELISA) kit (Life 
Technologies) was used according to manufacturer’s instructions. For analysis of 
endosomal Aβ42, endosomal membranes generated from each reaction of the cell-free 
assay were sonicated (2 x 10 pulses) and loaded onto the bottom of an ELISA well. Each 
experiment was performed at least 3 times. For experiments measuring Aβ42 secretion, 
100L of conditioned media was loaded onto wells and each sample was measured in 
duplicate. Each experiment was performed at least 3 times.  
 
2.13 Statistical Analysis—For the comparison of two means, a paired t-test was performed 
for the determination of significance. For the comparison of three or more means, a one-way 
ANOVA with post-hoc Tukey test was used to determine significance. A p-value of < 0.05 
was considered statistically significant with an n=>3.  
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Figure 2A. Discontinuous sucrose gradient for separation of endosomal 
subpopulations in primary cortical neurons. Post-nuclear supernatant was loaded at the 
bottom of a discontinuous sucrose gradient. After ultracentrifugation (150,000 x g for 60 min) 
interfaces accumulate material that corresponds to endosomal subpopulations.  
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Figure 2B. Schematic of the cell-free endosomal maturation assay. After obtaining an 
enriched population of early endosomes from a discontinuous sucrose gradient, the location 
of APP on these endosomes can be determined via susceptibility to trypsin cleavage. (a) 
Early endosomes from primary cortical neurons contain APP, as shown by immunoblot. (b) 
Treatment of early endosomes with trypsin results in a loss of APP immunoreactivity, 
suggesting APP is localized on the limiting membrane of these endosomes. (c) In our cell-
free assay, early endosomes are incubated with cytosol and an ATP regeneration system, 
that supports the formation of internal vesicles within endosomes. If APP is transported into 
internal vesicles it will be protected from protease treatment and APP will be visible on 
immunoblot. 
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Chapter 3. Endogenously Expressed Amyloid Precursor Protein (APP) is 
localized on neuronal endosomes  
Rationale: Pathological cleavage of APP into A fragments underlies the plaque 
pathology that is a hallmark of Alzheimer’s Disease. While we understand much about the 
enzymes involved in APP cleavage(3, 4, 89), the cellular location of these cleavage events 
is unclear. There is considerable evidence suggesting that endosomes may be the location 
of pathologic APP cleavage.  However, APP trafficking through endosomes is the subject of 
significant controversy in the scientific literature. In particular, the cytosolic requirements for 
APP movement from early to late endosomes and the implications of this movement for 
pathogenic processing are unclear. To address this scientific problem, I chose to use a 
cellular model, cultured primary cortical neurons, that is both physiologically relevant for 
Alzheimer’s Disease and is tractable for mechanistic examination. In this chapter, I address 
the characterization of this model.  
APP trafficking through endosomes has been observed in a variety of cell types, 
(194, 300, 305–307, 315). However, many of the published experiments examining APP 
trafficking have employed approaches including overexpression of exogenous APP or 
examination of trafficking events in heterologous non-neuronal cells. These experiments 
have greatly contributed to our understanding of APP movement through subcellular 
compartments, but it is unclear whether the results obtained are comparable to the itinerary 
of endogenous APP in neurons. To begin my approach of this scientific question, I 
examined whether endogenous APP is expressed in neurons in my preparation (cultured 
primary cortical neurons from E17 rat pup brains) at the time in culture when I would be 
investigating endosomal trafficking. Using immunocytochemistry and two different APP 
antibodies (Figure 3A), I observed that APP is expressed primarily in neurons (as shown by 
colocalization of APP with the neuronal marker, MAP2).  
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After establishing that APP was expressed in cultured neurons, I investigated 
whether APP is colocalized with endosomal markers in the absence of exogenous stimuli. I 
immunolabeled neurons using APP antibodies, as well as antibodies against endosomal 
marker proteins early endosomal antigen 1 (EEA1, a marker of early endosomes) and Rab7 
(a small GTPase that identifies late endosomal compartments). I observed that APP could 
be localized to distinct puncta that also contained one or another of these markers (Figure 
3B).  
 Because I was interested in examining the movement of APP through the endosomal 
pathway, I next determined whether early and late endosomal compartments from cultured 
neurons could be separated using velocity gradients, and whether APP would fractionate 
with endosomal markers in these preparations. Discontinuous sucrose gradients have been 
used extensively in the literature to separate fractions enriched in early and late endosomes 
(323, 324, 326). Using this technique, separation of post-nuclear supernatant derived from 
primary cortical neurons resulted in two major peaks (Figure 3C). The density of both 
endosomal peaks corresponds to reported values for the density of early and late 
endosomes (327). The peak observed in fractions 4 and 5 corresponds to lighter fractions in 
which both early and late endosomal markers have increased immunoreactivity. The peak 
observed in fractions 8 and 9 corresponds to more dense fractions where there is a peak in 
immunoreactivity for the EEA1 early endosomal marker. APP is enriched in both early and 
mixed endosomal peaks, although the APP-cleaving secretases BACE-1 and PS1 (a 
component of the gamma-secretase complex) are only enriched in the mixed endosomal 
fractions.  
 The Bean Laboratory has developed and characterized a cell-free endosomal 
reconstitution assay to investigate the movement of transmembrane proteins through 
endosomes (173, 296, 325). This approach examines the movement of a membrane protein 
from the limiting endosomal membrane into the internal endosomal vesicles that 
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corresponds to a critical step in which the cell determines whether a protein will be: (1) 
degraded in the lysosome, (2) become embedded in the lysosomal membrane, or (3) bud 
from the endosomal membrane for transport to other cellular compartments. In this 
approach, protease protection is used to follow the fate of an intracellular epitope of 
membrane proteins. Thus, when a transmembrane protein invaginates from the endosomal 
limiting membrane into internal vesicles within the endosomal lumen, it becomes 
inaccessible to the trypsin protease therefore assessing whether a membrane protein has 
entered the endosome lumen (refer to Figure 2B in Chapter 2). The movement of APP into 
endosomes renders its C-terminal tail inaccessible to trypsin, while APP residing on the 
endosomal membrane is susceptible to trypsin cleavage.  Protection of the APP C-terminal 
tail would happen as APP moves from the endosomal limiting membrane into internal 
vesicles.  
 We examined how accessible an APP C-terminal epitope was to trypsin treatment on 
endosomes that had been separated using a discontinuous sucrose gradient.  We 
hypothesized that in the early endosome, APP would be localized on the endosomal limiting 
membrane, suggesting that its C-terminal tail would be facing the exterior of the vesicle and 
would be cleaved by trypsin treatment. However, on the late endosome, we hypothesized 
that APP would have moved from the endosomal limiting membrane into internal vesicles 
within the mature endosome, and the APP C-terminal epitope would be inaccessible to 
trypsin.  
 We observed that APP was present on fractions enriched with early endosomes, and 
upon treatment by trypsin, immunoreactivity to APP using a C-terminal antibody was 
eliminated (Figure 3D). This suggested that the C-termini of most of the APP molecules 
present on early endosomes were exposed to the protease and that APP was therefore 
mostly residing on the limiting membrane of early endosomes. Interestingly, APP was also 
present on mixed endosomal fractions (that contain both early and late endosomes). 
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However, C-terminal APP immunoreactivity was not reduced by trypsin treatment on mixed 
endosomal fractions suggesting that the C-terminal of APP molecules on late endosomes 
was protected from proteolysis, perhaps because a large fraction of these APP molecules 
were already within the internal vesicles of late endosomes.  
These results suggest that endogenous APP is present in cultured primary cortical 
neurons and that endosomal fractions from these neurons can be separated and used in 
cell-free reconstitution reactions to investigate the mechanisms by which APP travels from 
the limiting endosomal membrane into internal vesicles, a critical step in determining the fate 
of the APP that transits this pathway.   
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Figure 3A. Endogenous APP is expressed in cultured rat cortical neurons. 
Cultured neurons were stained with fluorescent antibodies against APP, MAP2 (a neuronal 
marker), and DAPI (a nuclear stain), as shown by the first three panels A and B. The last 
panel is a merged image of all fluorescent channels.  (A) Cells present in the preparation 
were stained for both DAPI and MAP2 (rabbit antibody, Millipore). Most of the staining for 
APP (mouse antibody, Millipore) colocalizes with MAP2, suggesting the APP present in our 
culture is primarily expressed in neurons. (B) A different set of antibodies (rabbit anti-APP, 
Sigma; mouse anti-MAP2, Millipore) against the same target proteins reveal a similar result 
as in Panel A. Scale bar = 25 μm. The data shown in this figure was performed in 
collaboration with Francisco Rivera-Milián.  
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Figure 3B. Endogenous APP colocalizes with endosomal markers in primary 
cortical neurons at steady state. Neurons were fixed and stained with APP (first panel), 
endosomal markers (second panel), and the nuclear stain DAPI (third panel). The fourth 
panel represents a merged image of all fluorescent channels. Arrows mark distinct punctae 
where endosomal markers colocalize with APP.  (A) EEA1 is an early endosomal marker 
that colocalizes with endogenous APP at steady state. (B) Rab7 is a late endosomal marker 
that colocalizes with endogenous APP at steady state. Scale bar = 10um. The data shown in 
this figure was performed in collaboration with Francisco Rivera-Milián.  
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Figure 3C. Enrichment of endosomal subpopulations from cortical neurons 
through discontinuous sucrose gradient. Post-nuclear supernatant was loaded onto a 
discontinuous 8-40.6% sucrose gradient and centrifuged. Fractions were immunoblotted for 
endosomal markers (EEA1 for early endosomes and Rab7 for late endosomes), APP, and 
APP-modifying enzymes BACE1 and presenilin 1 (PS1, a component of the gamma-
secretase complex). Refractive index (RI) and calculated density of each fraction is reported 
at the bottom. A mixed endosomal peak was observed at fractions 4 and 5 (as shown by 
immunoreactivity to both EEA1 and Rab7), and an early endosomal peak was observed at 
fractions 8 and 9 (as shown by immunoreactivity to EEA1). 
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Figure 3D. APP localization on endosomes can be assessed by protease 
protection. Endosomal subpopulations were obtained from post-nuclear supernatant 
extracted from primary neurons, as described observed in Figure 3C. Untreated mixed 
endosomal fractions were analyzed via immunoblotting for presence of APP (lane 1). Upon 
treatment with trypsin, a protease, APP immunoreactivity persisted in this fraction (lane 2), 
suggesting APP is localized in a compartment inaccessible to trypsin (such as internal 
vesicles within the late endosome). Early endosome fractions were also analyzed for 
presence of APP (lane 3). Upon protease treatment, APP immunoreactivity was abolished 
(lane 4), suggesting APP in these endosomes is localized to a site accessible to trypsin, 
such as the endosomal limiting membrane. This experiment is representative of an 
experiment performed at least 3 times.  
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Chapter 4. Inward budding of endogenous APP into the mature endosome 
lumen  
Rationale: From the endosomal limiting membrane, transmembrane proteins can 
travel to different cellular destinations. The canonical route taken by membrane proteins 
involves movement from the endosomal limiting membrane into internal vesicles within the 
maturing endosome. Following transit into internal vesicles, membrane proteins can be 
degraded upon endosome-lysosome fusion or can be exported outside of the cell upon 
endosome-plasma membrane fusion. For membrane proteins to move from the endosomal 
limiting membrane into internal vesicles, cytosolic machinery is often required to sort 
proteins destined for internal vesicles from those that will remain on the limiting membrane. 
This movement of APP from the endosomal limiting membrane into internal vesicles has 
been suggested by others (305–307) to be a key location for amyloidogenic cleavage of 
APP. My previous results (Chapter 3) showed that APP is present on endosomes and that it 
is susceptible to protease cleavage on early, but not late endosomes suggesting that I could 
examine the requirements for endosomal APP trafficking, as well as how alterations in this 
trafficking might affect the fate of APP.  
 To investigate the mechanisms of endogenous APP trafficking from the endosomal 
limiting membrane into endosome lumen, I used a cell-free reconstitution assay previously 
characterized by the Bean laboratory (173, 296, 325). This assay relies on protease 
protection of cargo to examine movement of proteins (173, 328, 329), and it recapitulates 
endosomal maturation including accumulation of internal vesicles, the movement of 
membrane proteins from the limiting endosomal membrane into internal vesicles, and the 
dependence of membrane protein movement into internal vesicles on the cytosolic 
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machinery known as Endosomal Sorting Complexes Required for Transport (ESCRTs) (173, 
296).  
To confirm APP movement from the limiting endosomal membrane to internal 
vesicles, I separated early endosomes on a velocity gradient and incubated the early 
endosomes with rat brain cytosol or cytosol isolated from a parental S. cerevisiae (yeast) 
strain and an ATP regenerating system (Figure 4A). Inclusion of either mammalian or yeast 
cytosol in the reconstitution reactions was required to protect the APP C-terminal epitope 
from trypsin cleavage, suggesting that cytosolic components are necessary for the 
movement of APP from the endosomal membrane into internal vesicles.  
As summarized in the Introduction, the requirement of ESCRT machinery for the 
endosomal trafficking of APP is unclear. In particular, there is conflicting data on the role of 
early (ESCRT 0 and I) and late (ESCRT II and III) ESCRT complexes on APP trafficking 
(305, 307). In particular, deletion of early ESCRT components have been observed to both 
increase (306) and decrease (305, 307) amyloid production and secretion. I employed the 
cell-free reconstitution approach (as described in Figure 2B of Chapter 2) to directly 
determine whether ESCRT proteins are involved in APP movement from the endosomal 
membrane into its lumen.   
The capability of yeast cytosol to support APP movement into internal vesicles within 
endosomes allowed me to screen a yeast deletion library for proteins that might be required 
for the movement of APP from the limiting endosomal membrane into internal vesicles. I 
observed that components of all 4 ESCRT complexes are necessary for efficient APP 
movement into internal vesicles (Figures 4B, 4C). Thus, absence of ESCRT components 
from each of the four ESCRT complexes resulted in significant decreases in the protease 
protection of the C-terminal APP epitope, suggesting that these components are required for 
efficient movement of APP from the limiting endosomal membrane into the endosome lumen 
(Figure 4C).  
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The production of Aβ fragments is affected after deletion of ESCRT components, 
although previous studies did not address whether Aβ production in the absence of ESCRT 
components was endosomal (305–307). I investigated whether absence of ESCRT 
components affects endosomal production of Aβ42 within endosomes isolated from cultured 
neurons that had been used in the cell-free assay. Because of the limited endosomes 
obtained from each neuron, and the sensitivity limit of the ELISA, our assay does not allow 
for assessment of multiple Aβ species from one sample.  I focused on the Aβ42 species of 
APP cleavage product because of its reported increased pathogenicity and aggregation 
potential (41), compared to Aβ40, the other most common form of amyloid found in the 
human brain.  
Using the cell-free approach, with cytosol isolated from yeast strains lacking 
individual ESCRT components, I measured levels of endosomal Aβ42 following incubation 
of endosomal membranes with yeast cytosol lacking individual ESCRT components. I 
observed that Aβ42 levels were significantly increased in the absence of both early and late 
ESCRT components (Figure 4D), conditions that also resulted in decreased movement of 
APP into internal vesicles (see Figure 4C).  
I next examined whether immunodepletion of ESCRT components from mammalian 
cytosol would also affect endosomal Aβ42 levels. In particular, I wanted to understand 
whether deletion of an early ESCRT component affected APP trafficking, as the role of early 
ESCRT components in APP trafficking have been observed to both increase and decrease 
Aβ production and secretion (305–307). To this end, I immune-depleted rat brain cytosol of 
the mammalian early ESCRT, Hrs, and employed this cytosol in our cell-free endosomal 
reconstitution assay. I confirmed the depletion of Hrs using immunoblotting (Figure 4E). I 
incubated Hrs-depleted cytosol with APP-containing early endosomes in the cell-free 
endosome maturation assay and observed that the protease protection of APP was 
significantly reduced in Hrs-depleted conditions compared to IgG-treated cytosol (Figure 
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4F). Using a similar experimental design, I used endosomes in reactions with Hrs-depleted 
and control (IgG treated) cytosols and examined Aβ42 production. Interestingly, Aβ42 
production was dramatically increased in the absence of Hrs (Figure 4G).  
The results from these experiments suggest that ESCRT complexes may assist in 
the trafficking of APP through endosomes and confirm that absence of early and late 
ESCRT components result in increased Aβ42 accumulation in the endosomal lumen.  
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Figure 4A. APP movement from the endosomal limiting membrane into internal 
vesicles is mediated by cytosolic components. Early endosomes were isolated from rat 
cortical neurons using velocity gradients, as described (see Chapter 2), and incubated with 
cytosol isolated from yeast or rat brain. (A) Immunoblotting of early endosome fractions 
demonstrates that this fraction contains APP protein (lane 1). Treatment with trypsin results 
in the loss of APP immunoreactivity (lane 2), suggesting APP is present on the endosomal 
limiting membrane. Incubation of early endosomes with parental yeast cytosol results in 
persistent APP immunoreactivity despite trypsin treatment (lane 3). This suggests that 
cytosolic components can induce the movement of APP into trypsin-resistant compartments, 
such as the endosomal lumen.  (B) As in A, APP is present on early endosomal membranes 
(lane 1), and is susceptible to trypsinization (lane 2). Incubation with rat brain cytosol results 
in persistent APP immunoreactivity despite trypsin treatment (lane 3), suggesting that rat 
brain cytosol also supports movement of APP into internal vesicles.  
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Name 
ESCRT 
Mammalian 
Homolog 
ESCRT 
Complex 
 
Genotype 
 
Source 
BY4741 *parental 
strain 
--- MATa his3Δ1 leu2Δ0 ura3Δ0 
met15Δ0 
Dharmacon 
Δhse1 STAM1,2 ESCRT-0 MATa his3Δ1 leu2Δ0 ura3Δ0 
met15Δ0 hse::KANMX6 
Dharmacon 
Δvps23 Tsg101 ESCRT-I MATa his3Δ1 leu2Δ0 ura3Δ0 
lys2Δ0 vps23::KANMX6 
Dharmacon 
Δsnf8 Vps22/EAP30 ESCRT-II MATa his3Δ1 leu2Δ0 ura3Δ0 
lys2Δ0 snf8::KANMX6 
Dharmacon 
Δvps24 CHMP3 ESCRT-III MATa his3Δ1 leu2Δ0 ura3Δ0 
lys2Δ0 vps24::KANMX6 
Dharmacon 
 
Figure 4B. Yeast deletion strains used to examine the role of ESCRT machinery in 
APP endosomal trafficking. This table summarizes the Saccharomyces cerevisiae deletion 
strains for ESCRT components used in this study.  
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Figure 4C. Efficient trafficking of full-length APP depends on components of all 4 
ESCRT complexes. Early endosomal membranes containing APP were obtained using 
velocity gradients (see Figure 2C of Chapter 2). Endosomal membranes were incubated 
with cytosol isolated from yeast strains lacking ESCRT components (ΔHse for ESCRT-0, 
ΔVps23 for ESCRT-I, ΔSnf8 for ESCRT-II, and ΔVps24 for ESCRT-III).  Cytosol isolated 
from a parental yeast strain served as a reaction control. For these experiments, n=4 and (*) 
denotes p<0.05. 
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Figure 4D. Absence of early and late ESCRT components leads to increased Aβ42 
production. Early endosomes containing APP were isolated with from velocity gradients 
and incubated with yeast cytosol isolated from yeast strains lacking an early ESCRT 
component (ΔHse) or a late ESCRT component (ΔSnf8). After incubation, endosomes were 
collected and analyzed via ELISA for Aβ42 levels. The amount of Aβ42 present in 
endosomes following reactions containing cytosol from each deletion condition was 
normalized to the Aβ42 level obtained in a reaction containing cytosol isolated from a 
parental yeast control. For these experiments, n=4 and (*) denotes p<0.05.     
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Figure 4E. Immunodepletion of Hrs from rat brain cytosol.  Rat brain cytosol was 
prepared as previously described (173). Hrs was immunoprecipitated from cytosol, and 
equal amounts of cytosol were separated using SDS-PAGE and immunoblotted using anti-
Hrs antibody. .  
 
  
IgG Hrs
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Figure 4F. Depletion of Hrs significantly reduces APP movement into endosomal 
internal vesicles. Rat brain cytosol was immunodepleted of Hrs (see Figure 4E) and 
incubated with APP-containing early endosomes obtained from velocity gradients. After 
incubation and trypsin treatment, APP levels are significantly decreased in the ΔHrs 
condition, suggesting that Hrs is required for efficient movement of APP into internal 
vesicles within the endosomal lumen. For these experiments, n=3 and p=0.025.  
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Figure 4G. Absence of Hrs results in significantly increased Aβ42 in endosomes. 
APP-containing early endosomal membranes were incubated with cytosol that had been 
immunodepleted using anti-Hrs antibodies (see Figure 4E). After cell-free endosomal 
reconstitution reactions resulting endosomal membranes were recollected and analyzed by 
ELISA for Aβ42 levels. For these experiments, n=3, p=0.02.  
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Chapter 5. UBE4B is an E3 ubiquitin ligase that binds to, ubiquitinates APP 
and mediates efficient APP trafficking on endosomes 
Rationale: My data, along with the work of other groups, suggests a role for ESCRT 
proteins in the endosomal trafficking of APP. However, it is thought that ESCRT recognizes 
ubiquitinated cargo at the endosomal membrane. If so, APP must be ubiquitinated at this 
cellular location by a specific E3 ligase. I examined a candidate enzyme, UBE4B, and show 
that it affects APP trafficking at endosomes. My work suggests that UBE4B is a specific 
ligase that ubiquitinates APP at endosomes.   
  To determine whether APP can be ubiquitinated at steady state in cultured cortical 
neurons I immunoprecipitated APP and observed that it is ubiquitinated (Figure 5A).   I 
hypothesized that endosomally localized E3 ubiquitin ligases might be potential APP 
modifying enzymes that could affect APP trafficking at endosomes. In collaboration with Drs. 
Ritika Tewari, Monica Goss and Ting Wang we observed that one of these endosomally 
localized E3 ubiquitin ligases, UBE4B, co-immunoprecipitates with APP (Figure 5B) from 
neurons suggesting that APP and UBE4B can bind to each other.  
 To further elucidate the relationship between APP and UBE4B, I obtained SK-N-AS 
(a neuroblastoma cell line) that overexpressed UBE4B from another member of the lab, 
David Savage. I observed that SK-N-AS cells expressing increased UBE4B possessed 
significantly decreased levels of APP (Figure 5C) suggesting that there may be a 
relationship between UBE4B expression and APP stability.  
 I next used an shRNA against UBE4B in neurons to determine whether depletion of 
UBE4B would alter neuronal APP levels. The efficiency of lentiviral delivery was confirmed 
by infection of neurons with a virus containing GFP (Figure 5D). I then used this strategy to 
deliver an shRNA targeted toward UBE4B and a control shRNA containing a scrambled 
sequence. I observed that the shRNA containing a UBE4B target sequence resulted in 
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UBE4B protein depletion and decreased levels of APP in neuron lysate (Figure 5E), 
compared to the scrambled shRNA.  
 To assess whether UBE4B levels affected the state of APP ubiquitination in cortical 
neurons, I immunoprecipitated APP from neurons that had been treated with scrambled 
shRNA or shRNA against UBE4B. I observed that absence of UBE4B led to significantly 
decreased levels of APP ubiquitination (Figure 5F). 
 To determine whether UBE4B affects endosomal APP trafficking, I immunodepleted 
UBE4B from rat brain cytosol (Figure 5G) and used this cytosol in reactions containing early 
endosomes. Interestingly, immunodepletion of UBE4B did not significantly affect other 
endosomally associated cytosolic proteins that are known to bind UBE4B, such as Hrs 
(Figure 5H). Incubation of endosomes with UBE4B-depleted cytosol resulted in significantly 
decreased protease protection of the C-terminal epitope of APP compared to IgG-treated 
control cytosol (Figure 5I). These data suggest that UBE4B can ubiquitinate APP and that 
movement of APP into internal vesicles within the maturing endosome cannot occur 
efficiently in the absence of UBE4B.  
I next examined whether incubation of endosomes with UBE4B-depleted cytosol 
resulted in increased endosomal Aβ42 levels (Figure 5J). The increase observed was 
comparable to the Aβ42 increase observed when the early ESCRT Hrs was depleted in a 
similar experiment (See Chapter 4). To confirm that the Aβ42 was produced at endosomes 
during our cell-free assay, I performed cell-free reactions that included endosomes and the 
UBE4B-depleted cytosol, in the presence and absence of the BACE inhibitor, C3. I observed 
that reactions performed in the presence of the BACE1 inhibitor resulted in significantly 
decreased levels of Aβ42 compared to the amount of Aβ42 generated in the absence of this 
drug (Figure 5K). These data suggest that absence of UBE4B leaves APP more susceptible 
to cleavage by BACE-1, potentially due to increased time spent on the endosomal limiting 
membrane.    
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Figure 5A. APP is ubiquitinated at steady-state in primary cortical neurons. (A) APP 
was immunoprecipitated from neuron lysate (Lane 1). As a control, neuron lysate was 
incubated with a non-specific IgG control (Lane 2). (B) Ubiquitin co-immunoprecipitated with 
APP (Lane 1) but not with a nonspecific IgG (Lane 2). Together, these data suggest APP is 
ubiquitinated at steady state in primary cortical neurons.   
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Figure 5B. UBE4B co-immunoprecipitates with APP. Using lysate from the neuron-like 
cell line SK-N-AS, UBE4B was immunoprecipitated. Loaded material is shown in Lane 1. On 
immunoblotting, APP is shown to co-immunoprecipitate with UBE4B (Lane 2), but not with 
an IgG-treated control (Lane 3). Experiments performed in conjunction with Dr. Ritika 
Tewari.  
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Figure 5C. Overexpression of UBE4B leads to decreased APP levels in lysate. (A) 
UBE4B was overexpressed under a CMV promoter in SK-N-AS, a neuron-like human cell 
line (Lane 2). As a control, untransfected SK-N-AS cells are shown in Lane 1. (B) Increased 
UBE4B led to significantly reduced levels of APP in cell lysate, as demonstrated by 
quantitation. For these experiments, n=3 and p=0.03.  
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Figure 5D. Efficiency of lentiviral transfection in primary cortical neurons. Primary 
cortical neurons (as shown in the first panel) were successfully transduced with lentiviral 
particles packaged with a pFUGW plasmid (which encodes the GFP gene), as shown by the 
abundant expression of GFP in culture (second panel). The merged (third) panel 
demonstrates the high efficiency of transduction. 
 
 
 
 
 
 
 
Brightfield GFP Merged
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Figure 5E. UBE4B depletion in primary cortical neurons leads to increased APP levels 
in lysate. UBE4B was depleted from primary cortical neurons using lentivirally-delivered 
shRNA (as detailed in Chapter 2). As a control, neurons were also transduced with virus 
containing a non-specific shRNA (scrambled, Lane 1). Depletion of UBE4B was confirmed 
by immunoblotting (Lane 2). Depletion of UBE4B leads to significant increases in APP levels 
in lysate, as shown by quantitation. For these experiments, n=3 and p=0.04.  
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Figure 5F. Absence of UBE4B leads to decreased APP ubiquitination.  Lysates for 
immunoprecipitation were obtained from primary cortical neurons treated with lentivirus 
packaged with either scrambled or scrambled shRNA against UBE4B. (A) Left, a third of the 
material used for immunoprecipitation was used as a loading control. Right, lysates were 
immunoprecipitated with anti-APP or a nonspecific IgG control antibody. Immunoprecipitated 
materials were immunoblotted with antibodies against APP or ubiquitin. Immunoblot against 
ubiquitin was quantitated and normalized to immunoprecipitated APP in the scrambed and 
shUBE4B conditions. For these experiments, n=5 and p=0.041.   
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Figure 5G. Immunodepletion of UBE4B from rat brain cytosol.  UBE4B was 
immunodepleted from rat brain cytosol, and confirmed via immunoblotting (Lane 2). As a 
control, a separate sample of rat brain cytosol was immunodepleted with a nonspecific IgG 
control (Lane 1). UBE4B levels are markedly decreased in the ΔUBE4B condition, 
compared to IgG-treated cyotosol. 
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Figure 5H. Depletion of UBE4B does not affect Hrs levels in cytosol. UBE4B was 
immunodepleted from rat brain cytosol, and confirmed via immunoblotting (See Figure 5G). 
Immunodepletion of UBE4B did not affect levels of the early ESCRT component, Hrs, known 
to bind UBE4B and required for the efficient trafficking of many membrane proteins at 
endosomes, including APP (detailed in Chapter 4). Lane 1 shows IgG-treated cytosol. Lane 
2 shows cytosol immunodepleted for Hrs. Lane 3 shows cytosol immunodepleted for 
UBE4B.  
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Figure 5I. Absence of UBE4B leads to decreased APP protection from trypsin. APP-
containing early endosomes were incubated with IgG-treated cytosol (Lane 1) or ΔUBE4B 
cytosol (Lane 2). After trypsin cleavage, APP levels are significantly decreased in the 
ΔUBE4B condition, when compared to IgG control. In these experiments, n=4 and p=0.033.  
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Figure 5J. Absence of UBE4B leads to significantly increased levels of Aβ42 in 
endosomes.   APP-containing early endosomes were incubated with IgG-treated cytosol 
(Lane 1) or ΔUBE4B cytosol (Lane 2). After incubation, endosomes were recollected and 
analyzed for Aβ42 via ELISA. Aβ42 levels significantly increased in the ΔUBE4B condition, 
when compared to IgG control. In these experiments, n=3, p=0.04.  
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Figure 5K. Production of Aβ42, caused by absence of UBE4B, can be significantly 
decreased in the presence of the BACE inhibitor, C3. APP-containing early endosomes 
were incubated with 20uM C3 prior to incubation with ΔUBE4B cytosol. After endosomal 
recollection, endosomes were analyzed for Aβ42 levels via ELISA. For these experiments, 
n=4, p=0.019.  
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Discussion  
 
The trafficking of APP through subcellular compartments has been a matter of 
intense investigation because of the role that these trafficking events may play in its 
amyloidogenic cleavage.  Reports suggesting that APP may be cleaved at specific locations 
in the secretory and endocytic pathways have not clarified the primary sites underlying 
pathogenic APP fragment formation (3, 330–334). While the trans-Golgi network (TGN) and 
endosomes are likely important sites for production of Aβ, I focused my investigation on 
endosomal APP trafficking because of the strength of the evidence in favor of amyloid 
production at this cellular site. First, abnormal endosomal morphology and increased 
endosomal accumulation of pathogenic Aβ40 and Aβ42 peptides in the brain of individuals 
with dementia suggest that endosomal dysfunction may be key to its pathogenesis (335, 
336). Second, APP and β-secretase (BACE1) co-localize on endosomes (299, 300, 337, 
338). Third, both BACE1  (103, 112, 297)and the γ-secretase complex are enzymatically 
active at endosomes(83, 96, 123, 125). Fourth, BACE1 has optimal activity at the low pH 
found in endosomes(298, 339), and BACE1 inhibitors tethered to endosomes result in 
decreased APP processing into Aβ in vitro(340). Given the topology of APP on the 
endosomal membrane, amyloidogenic APP cleavage into Aβ would result in Aβ 
accumulation in the lumen of the endosome. Fifth, internalization of APP from the PM into 
endosomes is required for secretion of Aβ into the extracellular space(312, 315). These data 
point to endosomes as an important site for pathogenic APP cleavage. The findings of my 
dissertation contribute to this important scientific discussion as they approach the problem in 
a novel way, focusing on neuronal endosomes containing endogenous APP using 
biochemical and cell biological approaches. 
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6.1 Endogenously Expressed Amyloid Precursor Protein (APP) is localized on 
neuronal endosomes  
 The available literature on APP trafficking through endosomes has been confounded 
by the differences in cellular models (e.g. heterologous cell lines, neurons differentiated in 
vitro) used to study this process (3, 4, 89). Murine models have been used extensively in 
studies that inform our current understanding of Aβ production in the brain (341–344). I used 
a tractable model system that is relevant for APP processing in brain, primary cultured rat 
cortical neurons, to understand the cell biology of APP trafficking, 
To confirm that cultured cortical neurons from my preparations expressed APP, I 
performed a series of experiments using two different APP antibodies, as well as antibodies 
against the neuronal marker, MAP2 (see Figure 3A). The results from that experiment 
confirmed that APP is mostly expressed in neuronal cells in my preparations. Moreover, 
their morphology provides evidence that the neurons within my preparation are healthy (321, 
345, 346). It has been my experience that alterations in the culturing of these delicate cells 
greatly impacts the quality of the results obtained, and variance in neuronal health can 
interfere with observations. Aside from morphology, colocalization of APP with a neuronal 
marker (MAP2) provides evidence that in my preparation, APP is expressed in mostly in 
neruons, as opposed to glial cells or other brain associated cells that could contaminate 
cultures. In my experiments, no pharmacological agents were used to suppress the growth 
of supporting cells, so all experiments were performed between 5-10 days in vitro. It is 
important to note that these neurons are still considered developing neurons, which could 
impact my results. However, it is important to remember the conserved nature of the 
biological problem being examined and the fact that the mechanisms I have studied are 
similarly preserved in organisms across the eukaryotic taxon.  
Much of the previous research examining APP trafficking through endosomes has 
been performed using cell lines overexpressing APP, expressing tagged APP, or with 
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altered compartments that facilitate examination of their endosomal trafficking. This work 
has provided an essential framework that informs our current understanding of the itinerary 
of this protein within the cell, and that has laid the foundation for the work exposed in this 
dissertation. However, there are abundant examples in the scientific literature in which 
overexpression of a protein can saturate trafficking mechanisms in the cell in both endocytic 
and secretory pathways (347–349), and can obscure the interpretation of data generated 
under such conditions. Moreover, fusion of large epitope or fluorescent tags (e.g. green 
fluorescent protein (GFP) can change the protein structure or cause multimerization (350–
352), that can potentially alter protein function. For these reasons, examining the trafficking 
of endogenously expressed APP without the addition of tags is appealing and likely more 
accurately reflects trafficking in the human condition where APP is only overexpressed 
under limited circumstances, as in Down Syndrome (55, 64–66).  
To examine the trafficking of a membrane protein through endosomes, many studies 
employ pulse-chase methods in which binding of a ligand to a surface protein, triggers its 
internalization into endosomal compartments (353–356). However, the absence of an 
established ligand for APP (4) made the possibility of a pulse-chase experiment unfeasible. 
Although some studies have observed that events like synaptic activity can trigger APP 
internalization (315–317, 357), I wanted to understand whether, in the absence of 
investigator-driven stimuli, APP was localized in endosomal compartments. Our results 
confirmed that APP colocalized with early and late endosomal markers within our cellular 
model (Figure 3B), suggesting that in the absence of exogenous stimuli, APP enters the 
endocytic pathway as part of its typical itinerary.   
The use of velocity gradients to separate cellular organelles in a variety of tissues 
and cells (including neurons) has been extensively described (324, 327, 358, 359). I 
observed APP in fractions enriched in both early endosomes and fractions enriched in 
mixed (early and late) endosomes (Figure 3C). It is likely that the mixed endosomal peak 
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reflects intermediate states of the maturing endosome (150, 152, 154–156, 360).  
Interestingly, I observed that APP also peaks in fractions that coincide with the endosomal 
peaks, suggesting that, at steady state, APP can localize to endosomes. However, BACE1 
and PS1 (the enzymes that modify APP) seem to only be enriched in the mixed endosomal 
fraction. Other studies in the literature have observed APP-modifying enzymes to be present 
in endosomes (299, 300, 337), but their absence in early endosomal fractions suggests they 
can encounter APP at specific endosomal subpopulations. Despite this, it is still plausible 
that these enzymes are present (although not enriched) in early endosomal fractions, as 
evidenced by the accumulation of amyloid beta in in vitro assays, a product of the specific 
cleavage of APP by these enzymes.  
Since the fractions obtained from this gradient are not truly pure preparations of each 
endosomal subpopulation, I confirmed that protease protection (173, 328) was a way to 
assess the location of APP with respect to the maturing endosome (Figure 3D).  The 
differential response I obtained to protease protection with respect to the C-terminal epitope 
of APP in these two subpopulations allowed me to tailor a previously developed cell-free 
endosomal reconstitution assay (173, 296, 325) to the investigation of APP movement 
through endosomes.  
It is important to note that this gradient isolation of endosomes only separates these 
organelles based on their density. It cannot distinguish between endosomes destined to 
target particular neuronal projections, such as axons or dendrites, versus those localized to 
the neuronal soma (361–363). Two recent studies(299, 300) showed that APP interacted 
with BACE-1 preferentially at endosomes from dendritic spines, presynaptic boutons, and 
axons. However, while these endosomal subpopulations might have different cellular 
destinations, they have been characterized using endosomal markers similar to those used 
in this dissertation (299, 300). It is currently not possible to identify or separate these 
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subpopulations for in vitro use. Future studies could identify the neuronal location where the 
endosomal proteins identified in these studies affect APP trafficking in intact neurons.  
 
6.2 Inward budding of endogenous APP into the mature endosome lumen  
I observed that both yeast and mammalian cytosol supported the movement of APP 
from the endosomal limiting membrane into internal vesicles, as shown by the increase in 
protease protection that resulted from incubating these early endosomes with each type of 
cytosol (Figure 4A). This result provides further evidence of the conserved nature of 
endosomal trafficking machinery (as discussed in the Introduction). Furthermore, the 
successful implementation of this in vitro examination of APP trafficking in neuronal 
endosomes will allow future studies to examine the trafficking of other membrane proteins in 
the brain using this approach.   
The data presented supports our interpretation that trypsin protection can assess the 
location of APP with regard to the maturing endosome, and that cytosolic components 
support the development of internal vesicle formation in endosomes, even under cell-free 
conditions. Previous studies from the Bean laboratory have characterized this assay using 
other tools such as electron microscopy (173, 296, 325). However, it could be that the 
differential response to trypsin we observe in early vs mixed endosomal populations results 
from other factors (e.g. inhibitors to trypsin present in the preparation). In collaboration with 
Dr. Neal Waxham, I have performed preliminary experiments to address these questions 
and confirm that our in vitro assay can recapitulate endosomal maturation and internal 
vesicle formation in primary cortical neurons. In these experiments, we are using cryo-
electron microscopy to examine the distribution of multi-vesicular endosomes (which have a 
distinct morphology) in endosomal fractions obtained from discontinuous sucrose gradients. 
This will allow us to assess the degree of endosomal subpopulation separation yielded by 
the gradient by using a different parameter (endosome morphology) besides endosomal 
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molecular markers. This assessment will also allow us to confirm whether the cell-free 
endosomal reconstitution assay leads to quantifiable increases in multi-vesicular 
endosomes within our assay reactions. Published work from the Bean laboratory has 
previously used electron microscopy to confirm this in heterologous cell lines (173), but not 
in primary neuronal cultures.  
The acquisition of early endosomal membranes by using velocity gradients, and 
subsequent cell-free reactions yields very small amounts of material.  I observed that 
successful immunoblot detection of APP on endosomes required at least 10 million neurons 
per cell free reaction. For this reason, I limited my investigation of the role of ESCRT 
proteins in APP trafficking to one component per ESCRT complex (described in Figure 4B). 
Using the described assay and yeast deletion strains for a component of all ESCRT 
complexes, I observed that members of the ESCRT 0, I, II, and III complexes are needed for 
efficient movement of APP from the endosomal limiting membrane into internal vesicles 
(Figure 4C). These data confirm previous observations (305–307) that ESCRT proteins are 
involved in APP endosomal trafficking, and strengthen the evidence supporting the 
endocytic pathway as an important cellular site for APP trafficking in neurons.  However, 
there are differences in how these previous studies hypothesized endosomal production of 
Aβ occurs as a result of the absence of early (ESCRT-0, I) versus late (ESCRT-II, III) 
ESCRT proteins. As discussed in the introduction, Choy et al.(305) observed that deletion of 
early ESCRT components retained APP at endosomes and inhibited Aβ40 secretion, 
whereas deletion of a late ESCRT component redirected APP into secretory compartments 
and enhanced secretion of Aβ40. Morel et al.(306) observed that deletion of early ESCRT 
components also resulted in APP retention in endosomes (specifically, the endosomal 
limiting membrane), but led to increased Aβ40 secretion. Finally, Edgar et al.(307) observed 
that deletion of early ESCRT components led to increased intracellular Aβ40, but decreased 
Aβ40 secretion.  
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Using yeast deletion strains, I observed that absence of early and late ESCRT 
components led to a small but statistically significant increase in endosomal accumulation of 
Aβ42 (Figure 4D). Due to limitations in the amount of neuronal material available, I chose to 
only examine Aβ42 production in endosomes because of its increased pathogenicity and 
greater association with the development of AD (see Introduction), and because previous 
studies on the endosomal production of amyloid did not examine production of this species. 
Also, since there was significant controversy in the literature specifically regarding the role of 
early ESCRT proteins in amyloid production at endosomes (305–307), I examined how 
depletion of an early ESCRT, Hrs, affected APP trafficking. My results show that Hrs is 
required for efficient movement of full-length APP into the endosomal lumen (Figures 4E-F). 
Absence of Hrs dramatically increased Aβ42 production at endosomes (Figure 4G). 
There were differences in the levels of endosomal Aβ42 generated in cell-free 
reactions containing yeast cytosol compared with reactions containing mammalian cytosol. 
Although the endosomal trafficking machinery is generally well conserved across species, it 
appears that the requirements for amyloid production through cleavage of APP are less 
efficient in reactions containing yeast cytosol in our in vitro reconstitution assay. BACE-1, is 
a transmembrane protein (104) that is not present in the yeast genome (364), so it must 
therefore be contributed by its presence on neuronal endosomes. BACE-1 can cleave APP 
in cell-free conditions (365), suggesting it does not require other cofactors for this activity. 
The γ-secretase complex requires the integration of 4 members of the complex (presenilins 
1 and 2, APH, and nicastrin), none of which are expressed in yeast (366, 367) suggesting 
that they too are contributed on neuronal endosomes. The γ-secretase complex has been 
reconstituted by expression in yeast and shown to be sufficient for the cleavage of APP 
(368, 369). Thus, while both BACE-1 and the γ-secretase complex are capable of APP 
cleavage in the absence of co-factors, amyloidogenic cleavage of APP requires localization 
of APP and BACE-1 on lipid rafts (370–373). It is possible that the yeast cytosol does not 
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efficiently recapitulate this clustering of APP and the secretases in the appropriate 
endosomal microdomains.  
The observation of intra-endosomal accumulation of Aβ42 under conditions where 
both early (examined using yeast and mammalian cytosols) and late (examined using yeast 
cytosols) ESCRT components are deleted contrasts with the observations made by Choy et. 
al(305), where only absence of late ESCRTs led to increased amyloid production. Although 
my studies did not investigate the secretion of Aβ under conditions where ESCRTs were 
deleted from whole cells, my results are in accordance with the observations made by Morel 
et al. (306) and Edgar et al.(307) who showed that deletion of early ESCRTs causes 
generation of amyloid species in endosomes. The discrepancies in the results of these 
investigations might be due to differences in the cell model used, the type of APP examined 
(human vs. murine), and the degree of expression employed (exogenous vs. endogenous). 
However, my experiments do not address all aspects of the fate of APP in the absence of 
ESCRTs. It is likely that only a fraction of APP gets cleaved into amyloid at the endosome, 
and that some APP may be exported from endosomes in budded vesicles. This hypothesis 
is consistent with the observations made by Choy et al. (305), who showed that deletion of 
Hrs led to increased recycling of APP into the TGN. The cell-free assay used herein has 
been recently adapted to examine budding of vesicles from the endosomal limiting 
membrane (unpublished work from Bean laboratory). Such an approach could be used to 
examine whether APP may traffic from endosome-TGN in the absence of ESCRTs, and to 
elucidate the molecular machinery that may be required for this itinerary.  
My observations are limited to the production of Aβ42 at endosomes, but do not 
address where these endosomes may be targeted within neurons.  Late endosomes may 
fuse with the lysosome (174, 374, 375) or with the plasma membrane (168, 376, 
377)although the mechanisms distinguishing these fusion events are unclear.  Aβ 
production in these two different populations of endosomes would have different outcomes: 
 65 
in one case Aβ would remain inside neurons and in the other Aβ would be exported into the 
extracellular environment. Although the classical AD pathology involves aggregation of 
amyloid species outside of neurons, many studies (4, 51–53) have observed that 
intraneuronal accumulation of Aβ is toxic to neurons and might precede extracellular 
deposition. 
Finally, it is not clear whether the degree of amyloid production caused by 
endosomal disturbances is sufficient to drive AD pathogenesis. As discussed in the 
Introduction, animal models deficient in ESCRT proteins have severely affected phenotypes, 
and any in vivo investigation of the role of ESCRTs in amyloidopathies would be obscured 
by the many other afflictions that these animals would develop. However, Morel et al. (306) 
observed decreased expression of components of the endosomal sorting machinery in the 
brains of people with AD, suggesting that these defects might contribute to pathogenesis in 
humans.  
 
6.3 UBE4B is an E3 ubiquitin ligase that binds to, ubiquitinates APP and mediates 
efficient APP trafficking on endosomes 
 The involvement of ESCRT proteins in APP trafficking suggests that APP is 
ubiquitinated in its passage through the endocytic pathway, since ESCRT proteins enable 
endosomal sorting by binding to ubiquitin moieties on cargo proteins at the endosomal 
limiting membrane (203, 217, 256, 273, 378). In this regard, a previous publication(306) has 
demonstrated that APP is ubiquitinated at endosomes and that this ubiquitination facilitates 
its movement into mature endosomes. Aberrant ubiquitination has been correlated with AD 
(379–383), specifically the abnormal accumulation of ubiquitinated proteins inside 
endosomes of diseased neurons (384, 385). However, the identity of the E3 ligase (the 
ubiquitinating enzyme that is thought to provide specificity to the ubiquitination process, as 
detailed in the Introduction) that ubiquitinates APP at endosomes has been unclear. 
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 APP ubiquitination has been correlated with its trafficking in previous studies. 
Ubiquilin-mediated ubiquitination of APP has been observed, although it occurs in secretory 
compartments (386, 387), prior to insertion in the plasma membrane. Also, the E3 ligase 
FBL2 was identified by microarray data as a gene downregulated in the hippocampus of AD 
subjects (388). A follow-up study discovered that overexpression FBL2 decreased 
production of Aβ40 and Aβ42 in murine hippocampal neurons (319). Although FBL2 
expression did not significantly impact cellular APP levels, the study demonstrated that 
FBL2 can ubiquitinate APP at lysine 726 and increase its degradation (319). Interestingly, 
ubiquitination of APP by FBL2 at the cell surface inhibited APP endocytosis suggesting that 
FBL2 may play a role at the plasma membrane regulating APP internalization (Watanabe 
2012). In this regard, the ubiquitination of membrane proteins at the plasma membrane can, 
but does not always, trigger the internalization of membrane proteins (389–393). In another 
study (306), mutations of lysine residues 724-726 of APP led to decreased ubiquitination of 
APP, as well as increased Aβ40 production and retention of APP at the endosomal limiting 
membrane.  
 In my experiments, I observed that the E3 ligase UBE4B affects the endocytic 
trafficking of APP in neurons. It binds to APP, potentially affects its ubiquitination, and alters 
APP levels in lysate. My observation that APP levels are significantly increased in neuronal 
lysate in the absence of UBE4B underscores the importance of this ligase in APP 
homeostasis in neurons. The only other E3 ligase known to ubiquitinate APP, FBL2, does 
not affect cellular levels of full-length APP.  
As discussed in the Introduction, UBE4B has been implicated in the endosomal 
trafficking of other membrane proteins (296). In this previous study from the Bean 
laboratory, UBE4B is recruited to endosomes by binding to the early ESCRT protein Hrs. 
Depletion of UBE4B in HeLa cells did not affect levels of Hrs or other endosomally 
associated proteins in lysate, suggesting that it does not indiscriminately affect expression of 
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other important trafficking proteins (296). Of note, I observed that immunodepletion of 
UBE4B from rat brain cytosol did not affect Hrs levels, suggesting that the effects of UBE4B 
on APP endosomal trafficking observed with the cell-free assay are not due to depletion of 
Hrs.  
My results demonstrate that UBE4B aids in the efficient movement of APP through 
endosomes. It is important to underscore that the interaction between APP and UBE4B I 
examined in cell-free reconstitution reactions occurs at endosomes, where APP is located 
prior to incubation with UBE4B-containing cytosol. These results do not exclude upstream 
interactions between APP and UBE4B molecules, but highlight the consequences of this 
interaction at the endosomal limiting membrane. While these results emphasize the 
importance of UBE4B as an endosomally-associated peripheral membrane protein, it is 
important that future investigations identify whether other protein targets are affected by 
UBE4B at endosomes. If UBE4B has many endosomally localized targets whose trafficking 
is affected by its activity, it would complicate the potential exploitation of the UBE4B-APP 
interaction for therapeutic purposes.  
In my studies, the absence of UBE4B led to dramatic increases in endosomal Aβ42. 
The 7-fold increase in Aβ42 production observed in the absence of UBE4B is similar to the 
effect that deleting an ESCRT protein, Hrs, has on Aβ42 production. Further, the 
observation that pharmacological inhibition of BACE-1 in our cell-free assay leads to 
significant inhibition of the increases in Aβ42 production produced by Hrs or UBE4B 
depletion, suggests that active cleavage of APP by BACE-1 during the reaction incubations 
results in amyloid production. These observations suggest that endosomal sorting of wild-
type APP from the endosomal limiting membrane to internal vesicles within the endosomal 
lumen is a key regulatory step in the balance between APP elimination and Aβ production. 
In the context of endogenous expression of APP, depletion of Hrs and UBE4B leads to such 
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dramatic changes in Aβ42 production that it is possible that alterations in this APP trafficking 
step could result in pathological levels of Aβ in patients.  
Although the in vitro experiments performed in this dissertation propose a role for 
UBE4B in the formation of Aβ, the relevance of this result to in vivo conditions has yet to be 
examined. Deletion of UBE4B results in embryonic lethality in mice (289), so conditional 
knockouts would have to be generated to investigate whether absence of UBE4B in the 
brain could lead to accumulation of amyloid species, as would be predicted by my results.   
E3 ligases like UBE4B have been observed to confer specificity to the ubiquitination 
process, and are thought to have limited protein targets. This makes them suitable as 
potential therapeutic targets (200, 214, 216, 394), since alteration of their activity would 
likely have decreased potential for off-target effects. Future experiments could investigate 
the therapeutic role of UBE4B in the context of Aβ-related diseases like AD. For example, 
one might envision that overexpression of UBE4B could stimulate increased trafficking of 
APP into the endosomal lumen and may prevent Aβ production. Future investigations could 
explore UBE4B as a drug target for AD and other amyloidopathies of the brain.  
 
6.4 Future Directions 
The results discussed in this dissertation have examined the endocytic itinerary of 
APP, and determined that disruptions in this trafficking result in increased amyloid 
production. These findings also raise new questions that could drive further research in this 
field. 
 
1. To determine whether endosomally produced Aβ42 is actively secreted from neurons. 
A pressing question raised by the observation of endosomal accumulation of Aβ42 is 
whether this Aβ42 is secreted from cells. As discussed, intracellular Aβ can also be toxic to 
neurons, but previous work has shown that endosomal anomalies lead to increased Aβ 
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accumulation in conditioned media from cells (305–307). To address this question, I am 
pursuing experiments to examine how knockdown of UBE4B in neurons affects the 
accumulation of Aβ42 extracellularly.    
If it is the case that Aβ42 is secreted as a result of abnormalities at endosomes, how 
is this Aβ42 exported? As discussed in the introduction, endosomes can potentially fuse with 
the plasma membrane, and release its luminal contents and internal vesicles to the 
extracellular space. Evidence for this event is the observation of nanovesicles in the 
extracellular space that contain endosomal markers such as Tsg101 and the ESCRT-
associated protein Apoptosis-Linked Gene 2-Interacting Protein X (Alix) (178, 181, 183, 377, 
395). Upon secretion, these nanovesicles of endosomal origin are called exosomes, and are 
characterized as 100-200nm vesicles expressing endosomal proteins, such as Alix and 
Tsg101 (396), as well as lipid raft markers such as Flotillin(396, 397). Exosome release has 
been documented in a variety of cell types and body fluids (185, 186, 398, 399), including 
neurons (189–191). There is controversy regarding what physiological function exosomes 
have, and how they are secreted. However, in a 2008 study(168), Trajkovic and others 
observed that inhibition of nSMase2 (led to decreased release of exosomes. Since then, 
multiple studies have replicated this effect in a variety of cells (400, 401), including neuron-
like cells (192, 402). This effect has also been observed in in vivo experiments (403–405). I 
am actively pursuing experiments to address whether inhibition of endosome-PM fusion can 
block the release of endosomally accumulated Aβ42.  
 
2. To determine whether UBE4B can inhibit Aβ formation in the presence of disease-
inducing APP mutants.  
Another interesting aspect of these studies that could be explored is the potential for 
UBE4B to be used therapeutically to modulate production of Aβ. In the 2004 study by 
Matsumoto et al., the authors observed that overexpression of UBE4B led to decreased 
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accumulation of another toxic protein, ataxin 3, that is also a target of UBE4B ubiquitination. 
A similar strategy could be used in our investigations, where increased UBE4B could force 
degradation of the full-length APP, and lead to decrease Aβ42 levels induced by disease-
causing mutations in APP.  
The results of this dissertation suggest that UBE4B can ubiquitinate APP in living 
cells. However, the details of this ubiquitination were not explored. The work from Watanabe 
et al. and More at al. (306, 319) suggested that lysine residues 724-726 are crucial for APP 
ubiquitin. It would be interesting to verify whether these residues are ubiquitinated by 
UBE4B. This information would be beneficial not only for our mechanistic understanding of 
this relationship, but also because it would allow a more specific targeting of this interaction 
for therapeutic purposes.  
 
3.  To determine whether the itinerary of APP in endosomes leads to its degradation in 
lysosomes or its release via endosome-PM fusion. 
The observation of APP in exosomes (194, 199) is in contrast with previous work 
showing that APP gets degraded at the lysosome (122, 146, 147, 197, 406). This raises 
questions regarding the itinerary of APP after arrival at the late endosome, and could also 
be the subject of future investigations. Furthermore, if the itinerary of APP is release on 
exosomes via endosome-PM fusion, what advantage would this give neurons? Is exosomal 
APP physiologically relevant? Future projects could help clarify whether APP is lysosomally 
degraded in neurons, or exported in exosomes upon endosome-plasma membrane fusion. 
Moreover, if both observations are true, it would be of interested to investigate whether 
different subgroups of late endosomes lead to these divergences in the itinerary of APP, and 
what signals this segregation of APP on endosomes.   
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4.  To explore whether APP can traffic from endosomal compartments into outwardly 
budded vesicles, and how the retromer complex modulates this process.  
The subcellular site of APP cleavage into Aβ species has been highly controversial 
in the scientific literature (3, 4). My results suggesting that APP is processed through the 
amyloidogenic pathway at endosomes do not exclude the possibility that APP also gets 
cleaved into Aβ in secretory compartments. The retromer complex is a coat complex that 
has been established in retrograde trafficking from endosomes into the trans-Golgi network, 
TGN (137, 407–410). The retromer complex has been implicated in Alzheimer’s disease, 
although the direction of that relationship (whether increased or decreased expression of 
retromer components leads to Aβ formation) has been controversial (reviewed in (411)). 
Choy et al. (305) observed that ESCRT deficiencies led to retromer-dependent trafficking of 
APP into the TGN, where it was processed into Aβ. While my investigations did not examine 
this route of trafficking for APP, recent unpublished work by the Bean laboratory has 
adapted our cell-free assay to the examination of outward budding events from the 
endosomal limiting membrane. This assay could be adapted to evaluate whether neuronal 
endosomes traffic APP outwardly in a retromer-dependent matter, and whether those 
vesicles already contain endosomally produced Aβ or whether the processing truly occurs in 
the TGN.  
 
6.5 Conclusions  
 The findings of my dissertation contribute to the ongoing conversation regarding APP 
trafficking through endosomal compartments, and the production of Aβ as a result of 
trafficking disturbances. They address controversies in the literature regarding the role of 
ESCRT proteins in APP trafficking and Aβ production. Although these observations stem 
from in vitro reconstitution experiments, they suggest that, in the absence of pathogenic 
mutations in APP or the secretases, disturbances in endocytic trafficking of APP can lead to 
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marked increases in Aβ production. According to the amyloid cascade hypothesis (2, 41), 
imbalances in the production and clearance of Aβ can create a scenario that leads to brain 
disease, and the dramatic increases in Aβ production observed as a result of endocytic 
deficiencies in this study suggest that such mechanisms could underlie the pathogenesis of 
at least some individuals with AD and other diseases where Aβ accumulates.  
 A particular weakness of this investigation is the use of cell-free conditions to 
elucidate APP endosomal trafficking. While this assay has yielded information that I believe 
helps advance the field, the use of such assays disregards any regulatory mechanisms that 
the cell might employ to correct disturbances in trafficking. For example, it is feasible to 
envision how decreased UBE4B might, over time, lead the cell to also downregulate APP 
expression as a compensatory mechanism. In that sense, future experiments should design 
strategies that confirm these findings in whole cells, particularly neurons. However, the 
observation of how UBE4B impacts APP levels in lysate, as well as APP ubiquitination, lead 
me to believe that this compensatory mechanism might not be occurring, or at least might 
not occur before harm is done to the cell.   
Like with other complex diseases of aging, it is likely that individuals develop similar 
disease phenotypes of dementia due to distinct pathological mechanisms (412, 413). In that 
sense, the findings of this study do not disprove that Aβ production can happen at other 
cellular sites as have been described, particularly the secretory pathway (120, 147, 299, 
305). However, because Aβ accumulation is a common observation in demented patients, 
and dementia is so prevalent in our society, it is likely that endosomal cleavage of APP into 
Aβ is a relevant disease mechanism for at least some individuals.  
 Despite the significant controversies surrounding the pathogenesis of Alzheimer’s 
disease and the role that Aβ plays in that process, there is an overwhelming literature that 
suggests excess Aβ is toxic to neurons. However, multiple failures in the development of 
therapeutic strategies that target Aβ have led to decreased enthusiasm for Aβ as a target for 
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dementia (4, 48, 413). Studies during the last 5 years (including this dissertation) have 
allowed enhanced mechanistic understanding of Aβ production in cells, and have 
particularly highlighted the endocytic pathway. This new understanding of the cell biology of 
APP could aid in the development of new therapeutics for AD, especially in patients in which 
the disease is caused by endocytic trafficking disturbances. 
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